- Home
- SPHL vs CANF Comparison
SPHL vs CANF Comparison
Compare SPHL & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPHL | CANF |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPHL | CANF |
|---|---|---|
| Price | $5.81 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 5.9M | 564.4K |
| Earning Date | 12-29-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,956,226.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $3.36 |
| 52 Week High | $62.40 | $46.60 |
Technical Indicators
Market Signals| Indicator | SPHL | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 73.84 |
| Support Level | $4.14 | $3.87 |
| Resistance Level | $25.11 | $4.43 |
| Average True Range (ATR) | 2.41 | 0.34 |
| MACD | 0.52 | 0.06 |
| Stochastic Oscillator | 19.65 | 83.09 |
Price Performance
Historical ComparisonAbout SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.